Screening South African women for cervical pre-cancer using HPV testing
Studies HPV tests and cytology to screen women for cervical pre-cancer and cancer.
Key facts
- Who runs it
- University of Pretoria
- Where
- Pretoria, South AfricaSee the site
- Trial code
- Registry title
- Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.
- Status
- Recruiting
- People taking part
- 1,500 people, planned
- Started
- Dec 2016
- Expected to end
- Dec 2038
- Type of study
- Observational, 3 groups
- Treatments tested
- Screening
- Colposcopy
- LLETZ
- Record updated
- 7 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 25 to 75 in South Africa who come for or ask for a cervical cancer screening test. Women with and without HIV can join.
- Age
- 25 to 75 years
- Sex
- Women only
- Earlier treatment
- Women with current or previous treatment for gynaecological cancer cannot join.
Main reasons for not taking part
- Current pregnancy
- Hysterectomy
- Current or previous treatment for gynaecological cancer
- Hesitant or unable to undergo screening and treatment if indicated
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Informed consent accepted and signed
- Health seeking behaviour or request for a cervical cancer screening test
- Willing and able to receive test result by automated text message or clinic visit
Who cannot take part
- Current or previous treatment for gynaecological cancer
- Current pregnancy
- Hysterectomy
- Hesitant or unable to undergo screening and treatment if indicated
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 25 and 75 years old?
This trial is currently available in South Africa.
- Steve Biko Academic HospitalPretoria, South AfricaContact: Cathy Visser, MScTaking people
About the trial
What the trial wants to find out
Nearly 8 000 new cervical cancer cases are diagnosed in South Africa per year; many are still undiagnosed and about 50% of diagnosed cases succumb per year. Although the current prevalence of pre-cancer cervical disease is largely unknown, data from local studies suggest regional differences and an increase in the prevalence of cytological abnormalities when compared with historical data. Low frequency in cytology screening is the primary factor attributable to development of invasive cervical cancer and almost one-third of all cervical cancer patients had previous negative cytology. Due to the low sensitivity of cytology it can be assumed that the true prevalence of pre-cancer disease is underestimated by all available data. One round of optimal cervical cytology will detect around 50% of existing pre-cancer cervical disease as identified and proven using colposcopy and directed biopsy. It is now widely accepted that primary screening with a human papilloma virus (HPV) test can improve the sensitivity of screening and that even a single round of HPV screening can rapidly reduce the incidence of invasive cervical cancer and related mortality within a few years.
Read full original descriptionShow less
South Africa has a high prevalence of HIV infection and a delay in or failure to initiate antiretroviral therapy (ART). These facts, together with the largely unscreened status of the female population and the high incidence of cervical cancer all suggest that HPV infection and precursors to cervical cancer are both unusually common among South African women. Accurate current knowledge of the performance of newer generation HPV based screening tests in HIV-infected and general female population are essential for cost-analysis and planning for national prevention and screening programs. This study will aim to demonstrate the feasibility and efficacy of new generation HPV deoxyribonucleic acid (DNA) based screening assays in a South African setting.
The investigators hypothesize that HPV testing followed by normal and special cytology tests will be a successful screening model for a South African population.
The 3 groups in the trial
- HIV pos
those who serologically tested positive for HIV
Treatment: Screening, Colposcopy, and LLETZ
- HIV neg
those who serologically tested negative for HIV
Treatment: Screening, Colposcopy, and LLETZ
- HIV unk
those with no available serological test for HIV
Treatment: Screening, Colposcopy, and LLETZ
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women
- Plain-language title
- Screening South African women for cervical pre-cancer using HPV testingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT02956031, who can take part
- Publications
- Extended Genotyping as Triage of HPV Positive Screened Women in Low-and-Middle Income Countries.Journal of medical virology, 2026
- Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023
- Record updated
- 7 July 2026